| Form type | Sec Links | Description | Filing date | Reporting date |
|---|---|---|---|---|
| 10-Q | Report | Data | 10-Q | Nov 7, 2024 | Sep 30, 2024 |
| 8-K | Report | Data | 8-K | Nov 7, 2024 | Nov 7, 2024 |
| SC 13G/A | Report | Nov 4, 2024 | ||
| SC 13G | Report | SC 13G | Oct 31, 2024 | |
| 8-K | Report | Data | 8-K | Oct 31, 2024 | Oct 31, 2024 |
| 8-K | Report | Data | 8-K | Oct 24, 2024 | Oct 24, 2024 |
| 10-Q | Report | Data | 10-Q | Aug 7, 2024 | Jun 30, 2024 |
| 8-K | Report | Data | 8-K | Aug 7, 2024 | Aug 7, 2024 |
| 8-K | Report | Data | 8-K | Jun 26, 2024 | Jun 26, 2024 |
| 8-K | Report | Data | 8-K | Jun 14, 2024 | Jun 14, 2024 |
| 10-Q | Report | Data | 10-Q | May 6, 2024 | Mar 31, 2024 |
| 8-K | Report | Data | 8-K | May 6, 2024 | May 6, 2024 |
| 10-K | Report | Data | 10-K | Feb 28, 2024 | Dec 31, 2023 |
| 8-K | Report | Data | 8-K | Feb 28, 2024 | Feb 28, 2024 |
| SC 13G/A | Report | ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G/A(#1) | Feb 14, 2024 | |
| SC 13G/A | Report | SCHEDULE 13G/A | Feb 13, 2024 | |
| SC 13G | Report | Jan 29, 2024 | ||
| 8-K | Report | Data | 8-K | Nov 20, 2023 | Nov 16, 2023 |
| 10-Q | Report | Data | 10-Q | Nov 7, 2023 | Sep 30, 2023 |
| 8-K | Report | Data | 8-K | Nov 7, 2023 | Nov 7, 2023 |
| 8-K | Report | Data | 8-K | Sep 11, 2023 | Sep 11, 2023 |
| 10-Q | Report | Data | 10-Q | Aug 8, 2023 | Jun 30, 2023 |
| 8-K | Report | Data | 8-K | Aug 8, 2023 | Aug 8, 2023 |
| 8-K | Report | Data | 8-K | Jun 21, 2023 | Jun 16, 2023 |
| 8-K | Report | Data | 8-K | Jun 6, 2023 | Jun 1, 2023 |
| 10-Q | Report | Data | 10-Q | May 4, 2023 | Mar 31, 2023 |
| 8-K | Report | Data | 8-K | May 4, 2023 | May 4, 2023 |
| 10-K | Report | Data | 10-K | Feb 28, 2023 | Dec 31, 2022 |
| 8-K | Report | Data | 8-K | Feb 28, 2023 | Feb 28, 2023 |
| SC 13G/A | Report | SC 13G/A | Feb 13, 2023 | |
| SC 13G | Report | SCHEDULE 13G | Feb 9, 2023 | |
| 8-K | Report | Data | 8-K | Dec 16, 2022 | Dec 14, 2022 |
| 10-Q | Report | Data | 10-Q | Nov 8, 2022 | Sep 30, 2022 |
| 8-K | Report | Data | 8-K | Nov 8, 2022 | Nov 8, 2022 |
| 8-K | Report | Data | 8-K | Oct 24, 2022 | Oct 24, 2022 |
| 8-K | Report | Data | 8-K | Oct 6, 2022 | Oct 6, 2022 |
| 10-Q | Report | Data | 10-Q | Aug 4, 2022 | Jun 30, 2022 |
| 8-K | Report | Data | 8-K | Aug 4, 2022 | Aug 4, 2022 |
| 8-K | Report | Data | 8-K | Jun 13, 2022 | Jun 8, 2022 |
| 10-Q | Report | Data | 10-Q | May 10, 2022 | Mar 31, 2022 |
| 8-K | Report | Data | 8-K | May 10, 2022 | May 10, 2022 |
| 10-K | Report | Data | 10-K | Mar 29, 2022 | Dec 31, 2021 |
| 8-K | Report | Data | 8-K | Mar 29, 2022 | Mar 29, 2022 |
| 8-K | Report | Data | 8-K | Feb 15, 2022 | Feb 11, 2022 |
| SC 13G | Report | SC 13G | Feb 14, 2022 | |
| SC 13G | Report | SC 13G | Feb 14, 2022 | |
| SC 13G | Report | ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G | Feb 14, 2022 | |
| SC 13G | Report | SC 13G | Feb 11, 2022 | |
| SC 13G | Report | SCHEDULE 13G | Feb 10, 2022 | |
| 8-K | Report | Data | 8-K | Dec 17, 2021 | Dec 15, 2021 |
| 8-K | Report | Data | 8-K | Dec 3, 2021 | Dec 2, 2021 |
| 10-Q | Report | Data | 10-Q | Nov 12, 2021 | Sep 30, 2021 |
| 8-K | Report | Data | 8-K | Nov 12, 2021 | Nov 12, 2021 |
| 8-K | Report | Data | 8-K | Oct 28, 2021 | Oct 23, 2021 |
| 8-K/A | Report | Data | 8-K/A | Oct 1, 2021 | Sep 29, 2021 |
| 8-K | Report | Data | 8-K | Sep 30, 2021 | Sep 29, 2021 |
| 10-Q | Report | Data | 10-Q | Aug 12, 2021 | Jun 30, 2021 |
| 8-K | Report | Data | 8-K | Aug 12, 2021 | Aug 12, 2021 |